Endocrine-Related Cancer

Article	Citations
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	89
Radioiodine: 80 years and counting; the past, present, and future	65
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	53
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	49
Targeting growth hormone in cancer: future perspectives	43
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	42
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma	42
Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation	39
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	36
Congenital hypothyroidism and thyroid cancer	35
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	35
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy	34
Acknowledgement to reviewers	30
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	30
Celebrating the 80th anniversary of hormone ablation for prostate cancer	29
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	27
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	27
Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights	26
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma	26
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	26
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer	25
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	25
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	24
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	24
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	23

Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	22
Genetic disorders and insulinoma/glucagonoma	21
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	21
Acknowledgement to reviewers	20
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	20
AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes	19
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	19
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors	19
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	19
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	18
Update on the genetics of paragangliomas	18
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma	18
Nutrition, GH/IGF-1 signaling, and cancer	18
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	17
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	17
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	16
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	16
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	16
The role of vitamin D in breast cancer risk and progression	16
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	16
Evaluation of prognostic factors in advanced pediatric ACC	15
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	15
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	15
Aggressive versus indolent insulinomas: new clinicopathological insights	14
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	14
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	13
Metabolically active brown adipose tissue in PPGL: an observational cohort study	13
Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine	12
Genomic testing for RET in the clinic: UK and global perspective	12
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	12
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	12
Deiodinases in thyroid tumorigenesis	12
Molecular alterations in Hürthle cell nodules and preoperative cancer risk	12
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	12
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis	12
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	11
Genomic alterations impact cell cycle-related genes during prostate cancer progression	11
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	11
Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS	11
Cancer clocks in tumourigenesis: the p53 pathway and beyond	11
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	11
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	11
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	11
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	11
The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy	11
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	10
Prostate cancer and bone: clinical presentation and molecular mechanisms	10
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	10
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	10

The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	10
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	10
Talking about sex: erectile dysfunction in the oncology patient	9
Non-pituitary GH regulation of the tissue microenvironment	9
Activation of the HIF1α/TIMP1/MT6-MMP pathway is associated with invasion in pituitary null cell adenomas	9
Persistent pre-exhausted CD8+ T cells shape the tumor immune microenvironment in anaplastic thyroid cancer	9
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures	9
Beyond the three P’s: adrenal involvement in MEN1	9
Primary tumour resection in metastasised adrenocortical carcinoma	9
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	9
PARP inhibitors in advanced prostate cancer: when to use them?	9
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	9
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	9
Clinical and basic research implications of the article ‘IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer’	9
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	9
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal	9
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes	8
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes	8
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	8
Clinical, genetic, radiological characteristics and management of mediastinal paragangliomas: a literature review and case series	8
Radioiodine treatment: an historical and future perspective	8
A study of acromegaly-associated headache with somatostatin analgesia	8
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs	8
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	8
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	8
Germline CDKN1B variant type and site are associated with phenotype in MEN4	8
Genome-wide crosstalk between steroid receptors in breast and prostate cancers	8
Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer	8
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	8
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition	8
Therapy considerations in neuroendocrine prostate cancer: what next?	7
The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma	7
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	7
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway	7
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	7
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	7
Mendelian randomization to investigate the link between TSH and thyroid cancer	7
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	7
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	7
In memoriam: Charis Eng MD PhD (1962–2024)	6
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	6
Whole-exome sequencing of rectal neuroendocrine tumors	6
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	6
Factors associated with grade progression in pancreatic neuroendocrine tumors	6
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	6
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	6
Gender-affirming care and endocrine-related cancers	6
MicroRNAs as regulators of tumor metabolism	6
Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery)	6
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	6
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	6
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	6
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality	6
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	6
Needle tract seeding of thyroid cancer after biopsy of distant metastasis: a retrospective cohort	6
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	5
Mechanisms of RET-mediated signal transduction	5
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors	5
Response to Letter to the Editor regarding ‘Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma’	5
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	5
Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours	5
Insulin resistance and racial disparities in breast cancer prognosis: a multi-center cohort study	5
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	5
Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region	5
The effects of exercise and diet on sex steroids in breast cancer survivors	5
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy	5
Glucagon and insulin: 100 years young	5
Cushing syndrome from an ACTH-producing pheochromocytoma or paraganglioma: structured review of 94 cases	5
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians	4
RET@Thirty: the story behind identification of RET mutation as the cause of MEN2 and what it meant to clinical practice	4
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	4
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns	4
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	4
Sexual dimorphism in medullary thyroid cancer aggressiveness	4
Immunotherapy-induced isolated ACTH deficiency in cancer therapy	4
Transforming thyroid cancer management: the impact of neoadjuvant therapy	4
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers	4

The tumor microenvironment and immune responses in prostate cancer patients	4
Pacak–Zhuang syndrome: a model providing new insights into tumor syndromes	4
Novel insights in cell cycle dysregulation during prostate cancer progression	4
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	4
Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases	4
Antitumor immune response is associated with favorable survival in GEP-NEN G3	4
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	4
Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate	4
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	4
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	4
Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer	4
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings	4
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	3
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy	3
RAB5A in triple-negative breast cancer: a critical role in macrophage reshaping in an exosomal miR-21-dependent manner	3
lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling	3
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	3
Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?	3
Cellular mechanisms of RET receptor dysfunction in multiple endocrine neoplasia 2	3
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism	3
Second primary cancers and survival among neuroendocrine tumor patients	3
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	3
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	3
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	3
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	3
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy	3
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	3
Inhibition of activin signalling reduces the growth of LβT2 gonadotroph pituitary tumours in mouse	3
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors	3
Mechanisms of resistance to RET-directed therapies	3
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	2
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites	2
Bioengineered in vitro three-dimensional tumor models in endocrine cancers	2
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	2
Disease relapse in relation to lymph node sampling in lung carcinoid patients	2
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	2
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	2
Type 2 deiodinase is expressed in anaplastic thyroid carcinoma and its inhibition causes cell senescence	2
The thyroid risk score (TRS) for nodules with indeterminate cytology	2
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	2
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	2
Therapeutic inhibition of ATR in differentiated thyroid cancer	2
HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs	2
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	2
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	2
Precocious puberty due to intracranial germ cell tumors: a case–control study	2
GH-dependent growth of experimentally induced carcinomas in vivo	2
Effect of TSH levels during active surveillance of PTMC according to age	2
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	2
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	2
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	2
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	2
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	2
Systems-level liquid biopsy in advanced prostate cancer	2
SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?	2
Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis	2
C/EBPβ mediates anti-proliferative effects of 1,25(OH)2D on differentiated thyroid carcinoma cells	2
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer	2
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	2
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	2
Living with a RET gene mutation: patient perspectives	2
Percutaneous ablation of low-risk papillary thyroid cancer	2
100 years of the Warburg effect: a historical perspective	2
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	2